{"title":"Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.","authors":"Shuaijun Zou, Ruiqian Yao, Xiaoyan Yang, Erwen Kou, Sijia Huang, Hao Zhu, Liangzhe Wang, Julin Gu, Yuanjie Zhu","doi":"10.1080/07357907.2026.2675664","DOIUrl":null,"url":null,"abstract":"<p><p>The elevated incidence of second primary tumors (SPTs) has been reported in certain subtypes of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs), but remains unclear for overall primary cutaneous lymphomas (PCLs). Using Surveillance, Epidemiology and End Results (SEER) data, we analyzed 20,970 patients with PCLs and evaluated standardized incidence ratios (SIRs) and survival outcomes of SPTs stratified by lymphoma subtype (indolent vs. aggressive). A total of 2,589 SPTs were identified (SIR = 1.40, 95% CI 1.35-1.45), with significantly elevated risks across sex, ethnicity, stage, latency, year of diagnosis, and treatment. Both indolent and aggressive CTCLs were associated with increased SPT risk, with SIRs of 1.27 (1.16-1.39) and 1.38 (1.11-1.69), respectively. Lymphatic and hematopoietic malignancies predominated in indolent CTCLs, along with thyroid cancer, whereas aggressive CTCLs were mainly associated with extranodal non-Hodgkin lymphoma and myeloma. Increased SPT incidence was also observed in indolent and aggressive CBCLs (SIR = 1.49 and 1.38), with indolent CBCLs showing a broad SPT spectrum including lung cancer and cutaneous melanoma. Patients younger than 30 years, with stage I disease or aggressive PCLs, had decreased age-adjusted overall and disease-specific survival, indicating a need for more intensive surveillance.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"984-993"},"PeriodicalIF":2.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2026.2675664","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The elevated incidence of second primary tumors (SPTs) has been reported in certain subtypes of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs), but remains unclear for overall primary cutaneous lymphomas (PCLs). Using Surveillance, Epidemiology and End Results (SEER) data, we analyzed 20,970 patients with PCLs and evaluated standardized incidence ratios (SIRs) and survival outcomes of SPTs stratified by lymphoma subtype (indolent vs. aggressive). A total of 2,589 SPTs were identified (SIR = 1.40, 95% CI 1.35-1.45), with significantly elevated risks across sex, ethnicity, stage, latency, year of diagnosis, and treatment. Both indolent and aggressive CTCLs were associated with increased SPT risk, with SIRs of 1.27 (1.16-1.39) and 1.38 (1.11-1.69), respectively. Lymphatic and hematopoietic malignancies predominated in indolent CTCLs, along with thyroid cancer, whereas aggressive CTCLs were mainly associated with extranodal non-Hodgkin lymphoma and myeloma. Increased SPT incidence was also observed in indolent and aggressive CBCLs (SIR = 1.49 and 1.38), with indolent CBCLs showing a broad SPT spectrum including lung cancer and cutaneous melanoma. Patients younger than 30 years, with stage I disease or aggressive PCLs, had decreased age-adjusted overall and disease-specific survival, indicating a need for more intensive surveillance.
期刊介绍:
Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.